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Cancer mortality and morbidity is projected to increase significantly over the next few
decades. Current chemotherapeutic strategies have significant limitations, and there
is great interest in seeking novel therapies which are capable of specifically targeting
cancer cells. Given that fundamental differences exist between the cellular membranes
of healthy cells and tumor cells, novel therapies based on targeting membrane lipids in
cancer cells is a promising approach that deserves attention in the field of anticancer
drug development. Phosphatidylethanolamine (PE), a lipid membrane component which
exists only in the inner leaflet of cell membrane under normal circumstances, has
increased surface representation on the outer membrane of tumor cells with disrupted
membrane asymmetry. PE thus represents a potential chemotherapeutic target as the
higher exposure of PE on the membrane surface of cancer cells. This feature as well as
a high degree of expression of PE on endothelial cells in tumor vasculature, makes PE
an attractive molecular target for future cancer interventions. There have already been
several small molecules and membrane-active peptides identified which bind specifically
to the PE molecules on the cancer cell membrane, subsequently inducing membrane
disruption leading to cell lysis. This approach opens up a new front in the battle against
cancer, and is of particular interest as it may be a strategy that may be prove effective
against tumors that respond poorly to current chemotherapeutic agents. We aim to
highlight the evidence suggesting that PE is a strong candidate to be explored as a
potential molecular target for membrane targeted novel anticancer therapy.
Keywords: phosphatidylethanolamine, phospholipid bilayer, targeted drug, anticancer, membrane
permeabilization
INTRODUCTION
Cancer represents a major health concern globally. In 2012, cancer was responsible for 8 million
deaths, with an estimated 14 million new cases diagnosed. Recent decades have seen advances in the
diagnosis and treatment of cancer, but the overall reduction in cancer mortality is still limited; and
even more worryingly, cancer-related cases and deaths are projected to rise by at least 70% by 2030
(Ferlay et al., 2015; Antoni et al., 2016). Even if patients do successfully overcome cancer through
the current standard mainstays of treatment —namely chemotherapy and radiotherapy— the risk
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of reoccurrence of the disease is a major concern. Currently,
the main issues of concern relating to the currently available
therapeutic options are low therapeutic indices and a broad
spectrum of adverse effects (MacDonald, 2009). The key issues
underlying problems of potential toxicity as well as drug
resistance are attributed to the lack of specificity of existing
therapies toward tumor cells (Chari, 2007). Drug resistance can
be intrinsic because of variations between individual patients
and also due to the genetic differences in tumors (Gottesman
et al., 2002). Increasing evidence has demonstrated various
mechanisms by which cancer cells may acquire resistance such as
drug-detoxifying mechanisms, expression of one or more energy-
dependent transporters that extrude anticancer agent from the
cells before interaction with intracellular targets take place, or
acquiring the ability to evade drug induced apoptosis (Gottesman
et al., 2002; Perez-Tomas, 2006; Gillet and Gottesman, 2010;
Batist et al., 2011). Taken together, there is a mandate to develop
innovative therapeutic strategies to overcome the limitations
of current therapy, subsequently lowering the ever-increasing
cancer related mortality and morbidity.
In the late 1800s, bacteriologist Paul Ehrlich first
conceptualized the ‘magic bullet,’ a specifically synthesized
drug that would target a specific microorganism while not
harming any other cells in the organism. This concept has now
evolved into a more general field aiming to develop targeted
drug delivery strategies (Imai and Takaoka, 2006) to treat various
diseases including cancer and inflammatory diseases (Allen
and Cullis, 2004). Currently, these efforts have resulted in the
development of a full range of powerful molecular therapeutics
including monocompounds with targeting properties or a
cocktail of therapeutic compounds which may comprise
fusion proteins and nano/microparticles. The clinical success
of targeted drug delivery is highly dependent on its delivery
vehicle and its targets. In cancer treatment, a number of
targeting functions have been discovered such as tumor-antigen
recognizing antibodies (Kirpotin et al., 2006), ligands for
receptors (Pastorino et al., 2006) and RNA aptamers (Farokhzad
et al., 2006) against antigens which are expressed on the surface
of tumor cells. However, actually utilizing this discovery in
developing targeted drug delivery systems is limited by virtue of
the lack of an ubiquitously expressed tumor-specific antigen or
receptor on various cancer cells. Also, the geno- and phenotypic
heterogeneity of individual tumors (Marusyk et al., 2012) and
the co-existence of drug-susceptible and drug-resistant clones
(Greaves and Maley, 2012) further complicates targeted therapy.
In addition to the concerns involving treatment of localized
cancers, to date there has also been a lack of success in developing
an effective treatment for disseminated cancer. Over the last
few decades, it has been shown that the overall contribution of
curative and adjuvant cytotoxic chemotherapy has not resulted
in substantial improvement of treatment outcomes for most
cancer types (Bailar and Gornik, 1997; Morgan et al., 2004;
Ashdown et al., 2015). Thus, there is a clearly an urgent need
to pursue ground breaking, innovative ideas in developing
alternative chemotherapeutics that act specifically on clearly
defined biomarkers which are generally expressed within certain
tumor types in order to improve cancer cell selectivity of
chemotherapeutic agents. Considerable effort has been devoted
to developing novel targeted anticancer strategies such as specific
agents able to inhibit cancer cell proliferation (Parenti et al.,
2014), promote cell cycle regulation (Gabrielli et al., 2012)
and induce apoptosis or autophagy (Amaravadi et al., 2011).
However, a promising new approach targeting the cancer cell
membrane seems to have been underexplored thus far. This
approach focuses on destroying cancer cells by damaging their
cell membranes instead of binding to specific receptors. Here we
aim to highlight the prospect of phosphatidylethanolamine (PE),
an aminophospholipid on the cell membrane, as an attractive
target for anti-cancer therapy. A schematic diagram depicting
the potential of PE as molecular target for peptides and small
molecules exhibiting anticancer properties (Figure 1) has been
included.
MEMBRANE TARGETED THERAPY
Generally, most marketed drugs elicit their effects via direct
interaction with proteins (Melnikova and Golden, 2004; Adrian
et al., 2007); in fact, many new molecular entities are developed
for clinical use based on the previously elucidated structure of
their intended target proteins (Prathipati et al., 2007). However,
as increasing evidence emerges regarding the role of membrane
lipids in the regulation of numerous cellular functions and
activity of membrane proteins, membrane lipids have emerged
as an alternative molecular target (Lee, 2004, 2011). Given that
many cellular functions occur in or around the cell membrane,
alterations in the types and/or levels of membrane lipids may
have implications for many human pathologies, hence it was
proposed that therapies based on the regulation of membrane
lipids structure could be developed to control the molecular
events that are relevant to the various pathological states (Escribá,
2006). This has led to membrane-lipid therapy, which aims to
reverse the pathological state of the cell membrane by using
drugs that influence the membrane’s lipid organization via the
principle of structure-function, subsequently inducing changes in
cell signaling and gene expression (Escribá, 2006).
The development of cell membrane targeted cancer therapy is
made possible by the fact that there are fundamental differences
between the cell membrane composition of normal and cancer
cells. Non-cancer cells usually exhibit a more neutral total
membrane charge attributed to the presence of zwitterionic
phospholipids such as phosphatidylcholine and sphingomyelin
while phosphatidylserine (PS) and PE (are) located in the
inner leaflet of plasma membrane (Bevers et al., 1996). The
asymmetrical distribution of the phospholipids is maintained
by a group of P-type ATPases, aminophospholipid translocases
that use ATP hydrolysis to flip PS and PE from the external
to cytosolic leaflet (Chen et al., 1999). Unlike normal cells,
apoptotic cells and cancer cells lose their capacity to maintain
PS asymmetry, leading to the exposure of this lipid at the
cell’s outer membrane leaflet. PS is one of the molecules that
has gained interest in various clinical disciplines, particularly
in the development of non-invasive imaging technology to
support diagnosis and evaluation of treatment efficacy for various
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FIGURE 1 | The potential of PE as the novel molecular therapeutic target in anticancer treatment. The plasma membrane of normal cells is characterized
by an asymmetric distribution of various phospholipids over two membrane leaflet. PE resides in the inner leaflet facing the cytosol. The disrupted membrane
asymmetry of cancer cell with exposed PE to extracellular space serves as a molecular target for anticancer therapy. PE-binding peptides and small molecules
(ophiobolin A) bind specifically to the ethanolamine headgroup of PE. Upon binding, they disrupt and induce membrane destabilization via insertion into the lipid
bilayer. They also may induce membrane permeabilization via pore formation, subsequently lead to cell lysis and cell death. Furthermore, PE is also highly exposed
on endothelium cells in tumor vasculature. Targeting PE on endothelial cells in tumor vasculature could be a potential anti-angiogenesis approach to inhibit tumor
development.
diseases such as cancer and cardiovascular disease (Kenis and
Reutelingsperger, 2009). Furthermore, PS also represents an
attractive target for targeted drug delivery strategies that aim
to treat disease effectively with minimal detrimental side-effects.
Due to the limited PE-specific probes available to facilitate
the study of behavior of cell surface PE in living systems,
the functional significance of PE is less well-documented as
compared to that of PS. To date, duramycin and cinnamycin are
the only two well-known PE-binding peptides that have assisted
in unraveling many important biological functions of PE (Zhao,
2011).
PHOSPHATIDYLETHANOLAMINE AS AN
ANTI-CANCER TARGET
Phosphatidylethanolamine is the second most abundant
phospholipid on mammalian cellular membranes, accounting
for approximately 20% of the total phospholipids (Spector and
Yorek, 1985). Generally, PE is found predominantly in the
inner leaflet of the plasma membrane of viable mammalian
cells. In addition, PE is also abundant in the inner membrane
of mitochondria (Vance, 2008). Besides functioning as a
membrane structural element, the evidence suggests that PE
participates in many important pathophysiological cellular
processes (Vance, 2008; Calzada et al., 2016). It has been
demonstrated that translocation and redistribution of PE
occurs during a number of distinct biological events: (1)
cell division where it is externalized at the cleavage furrow
(Emoto et al., 1996); (2) cell death (for which exposure of PE
to extracellular environment is a molecular marker) (Emoto
et al., 1997); (3) anticoagulant mechanism where PE acts as a
cofactor for protein C (Tian et al., 2006). Given the diversity
in its biological roles, PE represents a distinct molecular target
among aminophospholipids and other membrane phospholipid
components.
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The development of PE-specific probes derived from
duramycin and cinnamycin has made possible the recent
discoveries of many biological functions of PE in living systems.
Duramycin is a highly specific PE-binding peptide produced
by Streptoverticillium cinnamoneus and is closely related to
cinnamycin (Ro09-0198) which is produced by Streptomyces
sp. (Iwamoto et al., 2007). Both duramycin and cinnamycin
are lantibiotics, bacteriocins which are characterized by the
presence of a high proportion of unusual thioether amino acids
(lanthionine and methyllanthionine). Lantibiotics are toxic
toward many Gram-positive bacteria, but the toxic effects of
cinnamycin are not limited to bacterial cells. Duramycin and
cinnamycin were also found to display a number of effects on
eukaryotic cells, such as induction of hemolysis (Choung et al.,
1988a), inhibition of phospholipase A2 or interference with
prostaglandin and leukotriene biosynthesis (Märki et al., 1991).
Most of these effects described can be explained by the specific
binding of these lantibiotics to PE (Choung et al., 1988b; Hosoda
et al., 1996).
Both duramycin and cinnamycin are unique in that they
bind to PE located in the inner layer of the plasma membrane
in mammalian cells. They bind with high affinity to the head
group of PE at a molar ratio of 1:1 with a dissociation
constant in the nanomolar range (Zhao et al., 2008). Given
that they specifically bind to PE, they have been employed
to study the distribution and metabolism of PE in different
biological systems. The binding of cinnamycin to PE was found
to induce transbilayer phospholipid movement of target cells
in a PE-dependent manner (Makino et al., 2003). This study
demonstrated that the binding of cinnamycin induces membrane
reorganization that eventually leads to cell death (Makino et al.,
2003). In addition to inducing transbilayer lipid movement, there
is preferential binding of both duramycin and cinnamycin to
areas of membrane with high curvature and further binding of
the peptides is promoted via membrane tubulation (Iwamoto
et al., 2007).
In addition to duramycin and cinnamycin, cyclotides
represent a new lipid-binding protein family of cyclic peptides
which exert their biological activities by acting on cell
membrane, particularly by binding to phospholipids containing
PE headgroups. Studies have shown that the cyclotides
interact and bind specifically with membranes containing
PE-phospholipids as compared to other lipids lacking PE-
phospholipids and their binding was followed by insertion
that subsequently led to membrane disruption (Henriques
et al., 2011, 2012; Troeira Henriques et al., 2014). Wang
et al. (2012) proposed that the binding of cyclotides to cell
membrane surface via interaction with PE-lipid headgroup
resulted in formation of pores based on barrel-stave or toroidal
pore models when a threshold concentration is exceeded. The
toxicity of cyclotides were shown to be dependent on PE
exposure at the membrane surface. Although cyclotides were
found to be equally toxic toward cancerous and non-cancerous
cell, cyclotides can recognize cancer cells more efficiently
than non-cancerous cells at non-permeabilising concentrations
(Troeira Henriques et al., 2014). Hence, the higher proportion
of exposed PE on the outer membrane of cancer cell
presents a potential molecular target for those membrane-
active peptides to exert their cytotoxic effects. In addition,
PE was found to play a role in enhancing the susceptibility
of the membrane to permeabilization by bound peptides and
also facilitating the formation of larger transmembrane pores
(Leite et al., 2015). These findings open up new avenues
toward the development of novel chemotherapeutic peptides that
specifically recognize PE phospholipid components on cancer
cells and induce membrane disruption upon binding, leading to
membrane permeabilization via pore formation and eventually
cell death.
Despite numerous successful examples of membrane active
peptides in in vivo studies, to date none of them have made it
into the pharmaceutical market. Potential issues including poor
bioavailability and potential toxicity of peptides are hampering
the progress and development of peptides as novel anticancer
agents. Furthermore, peptide degradation due to serum proteases
is also a major challenge limiting the stability and half-life of these
molecules (Adessi and Soto, 2002).
A recent study has found that a natural product, ophiobolin
A (OPA) exerts its cytotoxicity toward cancer cells by
forming a pyrrole-containing covalent cytotoxic adduct with the
ethanolamine head group of PE, subsequently leading to lipid
bilayer destabilization (Chidley et al., 2016). OPA is a plant
toxin isolated from pathogenic fungi of the Bipolaris genus that
exhibits cytotoxicity at nanomolar concentrations against a range
of cancer cell lines. Basically, the study performed an unbiased
genome-wide approach to identify the molecular target of OPA
through insertional mutagenesis of near-haploid cell line KBM7
using retroviral gene trap approach and demonstrated that OPA
forms PE-OPA adducts associated with membrane disruption
and eventual cell death (Chidley et al., 2016). This discovery
highlighted the potential importance of PE as the molecular
target for small molecules which provides further impetus to
pursue targeting PE as a novel chemotherapeutic approach,
particularly against cancer types which are known to respond
poorly to current chemotherapy.
Additional information from a recent study revealed that PE
is highly exposed on tumor vascular endothelium, suggesting
that it may serve as a marker for imaging tumor vasculature
and also drug targeting (Stafford and Thorpe, 2011). Targeting
the angiogenesis-driven sprouting of new vessels has seen a
revolution in anti-cancer drug development in the past decade.
Angiogenesis and tumor vascularization are crucial to the growth
and metastasis of cancers (Folkman, 2002; Berretta et al., 2016).
The observation that tumors cannot grow beyond a size of
approximately 2 mm3 without the support of neovascularization
(Folkman, 1971) has led to clinical development of a large
number of angiogenesis-inhibiting agents that act on a number of
potential targets, including the matrix-metalloproteinases, tissue
plasminogen activator (Pepper, 2001), angiogenic cytokines
and vascular endothelial cells (Dvorak, 2002) participating in
angiogenesis. Therefore, the selective exposure of PE on tumor
vasculature may present an opportunity for selective therapeutic
intervention, whereby specific PE-binding peptides or antibodies
can be employed to direct or deliver the bound endothelial
cell-damaging agents to the site of action.
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CONCLUSION AND FUTURE
DIRECTIONS
To date, the success of cancer therapies is limited by their
severe side effects and also the problems of drug resistance.
These issues make it vital to explore potential molecular targets
for anticancer therapy like PE which have strong potential
for translation into future clinical applications. A number
of membrane-active peptides and small molecules have been
shown to bind PE specifically, subsequently eliciting membrane
disruption. The ability of those molecules to recognize cancer
cells is PE dependent, suggesting that PE is an efficient
means of targeting cancers. This notion is strengthened
further by the finding that the levels of PE exposure on
the outer membrane leaflet is particularly high on cell
surfaces exposed to stress conditions associated with tumor
microenvironments. However, optimization and modification
of peptides are required to enhance their selective interaction
with their target on the cell membrane as well as reducing
toxicity and development of drug resistance. The knowledge
of these PE-binding peptides and small molecules has the
potential to assist in the design of novel drugs based on
their molecular scaffold, perhaps allowing development of
molecules capable of targeting specific cell types. Based on
the concept of membrane disruption via binding of PE,
suitable assays employing high-throughput screening strategy
can be used to identify novel PE-binding molecules from large
libraries of drug candidates before optimization in terms of
their potency, selectivity, physicochemical, pharmacokinetic, and
toxicity properties.
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